Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7003240 | 1.00 | MAPK1 (0.43) | MAPK1KDM4EALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL94206 | 1.00 | MAPK1 (0.43) | MAPK1KDM4EALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL132894 | 0.94 | MAPK1 (0.42) | MAPK1L3MBTL3L3MBTL1TP53BP1SRD5A2 | |
| SCHEMBL863778 | 0.91 | MAPK1 (0.43) | MAPK1KDM4EALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL11008209 | 0.87 | MAPK1 (0.43) | MAPK1KDM4EALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL11003669 | 0.85 | MAPK1 (0.42) | MAPK1L3MBTL3L3MBTL1OPRM1OPRL1 | |
| SCHEMBL863645 | 0.85 | MAPK1 (0.42) | MAPK1L3MBTL3L3MBTL1TP53BP1OPRM1 | |
| SCHEMBL8149056 | 0.85 | MAPK1 (0.33) | MAPK1KDM4EALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL1822607 | 0.84 | MAPK1 (0.45) | MAPK1ALDH1A1L3MBTL3L3MBTL1CTDSP1 | |
| SCHEMBL30761740 | 0.83 | MAPK1 (0.41) | MAPK1ALDH1A1L3MBTL3L3MBTL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-29 | — | — | US | disclosed |
| EP-3672960-A2 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | Acadia Pharmaceuticals Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019040106-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040104-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| EP-1361225-B1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | SANKYO CO (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-7091352-B2 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | SANKYO COMPANY, LIMITED (JP) | 2005-07-21 | — | — | US | disclosed |
| EP-1541571-A1 | BICYCLIC UNSATURATED TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20040147525-A1 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1361225-A1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | Sankyo Company, Limited (JP) | 2003-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | IL1B, IL1A, STAT6 | MAPK1 285/4885KDM4E 4161/4885ALDH1A1 462/4885 |
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, VHL, CYP11B2 | MAPK1 3496/4885KDM4E 3819/4885ALDH1A1 321/4885 |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, VHL, CYP11B2 | MAPK1 3496/4885KDM4E 3819/4885ALDH1A1 321/4885 |
| US-20040147525-A1 | Compounds substituted with bicyclic amino groups | IL2, IL1B, IL4I1 | MAPK1 733/4885KDM4E 3358/4885ALDH1A1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.